RNS
MYGN icon

Robert N. Shapiro’s Myriad Genetics MYGN Stock Holding History

Robert N. Shapiro’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,920
Closed -$45K – 846
2013
Q3 		$45K Hold
1,920
– – 0.01% 616
2013
Q2 		$52K Buy
+1,920
New +$55.6K 0.01% 551

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LCG
Luxor Capital Group New York $1.43B AUM 30.88% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Robert N. Shapiro's MYGN Position: Q4 2013 in Review

Robert N. Shapiro sold out of Myriad Genetics (MYGN) in Q4 2013, closing a stake of 1,920 shares — an estimated $45K sold.

Robert N. Shapiro first reported a position in MYGN in Q2 2013 and held it in 2 quarters. The position peaked at $52K in Q2 2013. 270 funds tracked by Wall St. Rank hold MYGN as of Q4 2013.

  • Robert N. Shapiro reported no remaining Myriad Genetics position as of Q4 2013 after selling out during the quarter.
  • Robert N. Shapiro sold 1,920 Myriad Genetics shares in Q4 2013, an estimated $45K.
  • Robert N. Shapiro first reported a position in Myriad Genetics in Q2 2013 and held it in 2 quarters.
  • Robert N. Shapiro's Myriad Genetics position peaked at $52K in Q2 2013.
  • 270 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2013.

Based on Robert N. Shapiro's 13F filing for Q4 2013, filed 6 Feb 2014.